A Single Arm, Open-label Study to Evaluate the Efficacy on Tumor Response and the Safety of Bevacizumab and Trastuzumab Combination and Sequential Capecitabine in Patients With HER2 +Ive Locally Recurrent or Metastatic Breast Cancer After Early Relapse to Adjuvant Trastuzumab-containing Therapy.

Trial Profile

A Single Arm, Open-label Study to Evaluate the Efficacy on Tumor Response and the Safety of Bevacizumab and Trastuzumab Combination and Sequential Capecitabine in Patients With HER2 +Ive Locally Recurrent or Metastatic Breast Cancer After Early Relapse to Adjuvant Trastuzumab-containing Therapy.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Trastuzumab (Primary) ; Docetaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 23 May 2013 Planned End Date changed from 1 Jun 2014 to 1 Aug 2013 as reported by ClinicalTrials.gov.
    • 06 Sep 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 18 Apr 2012 Status changed from discontinued to completed as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top